Search
Position of EHA on the Harmonization of Training and Education in Europe
The challenge
Education and training are largely national competencies.
Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases
Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.
Read moreEuropean Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
European registry on inherited platelet disorders project, February 2025
A project update from Prof Paolo Gresele. We successfully completed the CRF harmonization phase and are now in the process of finalizing and launching the registry platform.
Read moreEHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects of the disease!
Live days: April 29-30, 2021
Content available: April 22, 2021 – May 29, 2021
Chair: Prof Dr C Dufour
Junior and senior hematologists from all over the world gathered on April 29-30, 2021 for the live days of the EHA-SWG Scientific Meeting on…
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
Read moreRestoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read more